drugset / Trial / NCT06445959
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Timeline
- Start
- 2024-08-29
- Primary completion
- 2027-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | — | Intravenous |
| Subject | Decitabine/cedazuridine | Unknown | — | Oral |
| Subject | Olutasidenib | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |
Indications
No indication recorded.